New biotech advances RNA therapies for rare genetic cardiomyopathies
Unresolved biotech is advancing RNA therapeutics for rare genetic cardiomyopathies, focusing on PRKAG2 and PLN syndromes. Lead program is in Phase I/II, with proof-of-concept data expected next year and strategic partnerships supporting the pipeline.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.